SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
20 avr. 2021 07h00 HE
|
SparingVision
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis...
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
20 avr. 2021 01h00 HE
|
SparingVision
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis...
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
19 mars 2021 08h00 HE
|
SparingVision
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
19 mars 2021 02h00 HE
|
SparingVision
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
SparingVision Conference Participation in H1 2021
16 févr. 2021 07h00 HE
|
SparingVision
SparingVision Conference Participation in H1 2021 Paris, February 16, 2021 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases,...
SparingVision Conference Participation in H1 2021
16 févr. 2021 01h00 HE
|
SparingVision
SparingVision Conference Participation in H1 2021 Paris, February 16, 2021 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases,...
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
04 févr. 2021 01h00 HE
|
SparingVision
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of...
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
04 févr. 2021 01h00 HE
|
SparingVision
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of...
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
29 janv. 2021 07h00 HE
|
SparingVision
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
29 janv. 2021 01h00 HE
|
SparingVision
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...